The therapeutic ef®cacy of drugs that suppress gastric acid secretion in the healing of peptic ulcers and gastrooesophageal re¯ux disease (GERD) depends on the potency of acid suppression.1, 2 The proton pump inhibitors, which cause potent and long-lasting inhibition of the terminal step in gastric acid secretion, are considered to be the most effective medical treatment for the management of patients with acid-related diseases.3, 4 However, interindividual variations in the suppressive effect of proton pump inhibitors on gastric acid secretion have been reported. 5±7 Helicobacter pylori infection is reported to affect the acid suppressing effect of proton pump inhibitors and is regarded as one of the factors that cause interindividual variations in their effect.
8±12Recently, it has also been found that CYP2C19, which is one of the isoenzymes of cytochrome P450 (CYP) in the liver and has important roles in the catabolism of proton pump inhibitors, has two genetically determined phenotypes: extensive metabolizers (EMs) and poor metabolizers (PMs).13±17 Variation in phenotype affects the acid suppressing effects of omeprazole by changing its rate of catabolism.18 These two phenotypes of CYP2C19 can be determined by measuring urinary 4¢-hydroxymephenytoin excretion or urinary S/R enantiomeric ratio after a single dose of racemic SUMMARY Background: CYP2C19 has an important role in the catabolism of several proton pump inhibitors. However, the relative contribution of CYP2C19-mediated metabolism varies among the different proton pump inhibitors. Aim: To determine the effect of CYP2C19 genotype status on intragastric pH during dosing with lansoprazole or rabeprazole. Subjects and methods: The subjects were 20 male volunteers without Helicobacter pylori infection. Their CYP2C19 genotype status was determined by a polymerase chain reaction-restriction fragment length polymorphism method. Twenty-four-hour monitoring of intragastric acidity was performed three times: once
Nocturnal exposure of the esophagus to acid occurs frequently in patients with LA grades C and D esophagitis. Thus, the existence of NAB with resulting nocturnal acid reflux should be considered when the patient with high-grade esophagitis shows resistance to PPI treatment.
SUMMARYBackground: An effective therapeutic strategy for functional dyspepsia (FD) has not been well-established. Aim: We investigated and compared the therapeutic effects of famotidine, mosapride and tandospirone for the control of dyspeptic symptoms. Methods: Fully examined FD patients of outpatient clinics at seven different medical centres were enrolled in the study. They were randomly assigned to three groups based on the type of drug administered: famotidine, mosapride and tandospirone. The effects of
The degree of arterial stiffness in H. pylori-positive young subjects is higher than that in H. pylori-negative young subjects. However, no difference between the arterial stiffness values of H. pylori-seropositive and -seronegative elderly individuals was observed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.